41
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Stromal Liver Kinase B1 [STK11] Signaling Loss Induces Oviductal Adenomas and Endometrial Cancer by Activating Mammalian Target of Rapamycin Complex 1

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Germline mutations of the Liver Kinase b1 ( LKB1/STK11) tumor suppressor gene have been linked to Peutz-Jeghers Syndrome (PJS), an autosomal-dominant, cancer-prone disorder in which patients develop neoplasms in several organs, including the oviduct, ovary, and cervix. We have conditionally deleted Lkb1 in Müllerian duct mesenchyme-derived cells of the female reproductive tract and observed expansion of the stromal compartment and hyperplasia and/or neoplasia of adjacent epithelial cells throughout the reproductive tract with paratubal cysts and adenomyomas in oviducts and, eventually, endometrial cancer. Examination of the proliferation marker phospho-histone H3 and mammalian Target Of Rapamycin Complex 1 (mTORC1) pathway members revealed increased proliferation and mTORC1 activation in stromal cells of both the oviduct and uterus. Treatment with rapamycin, an inhibitor of mTORC1 activity, decreased tumor burden in adult Lkb1 mutant mice. Deletion of the genes for Tuberous Sclerosis 1 ( Tsc1) or Tsc2, regulators of mTORC1 that are downstream of LKB1 signaling, in the oviductal and uterine stroma phenocopies some of the defects observed in Lkb1 mutant mice, confirming that dysregulated mTORC1 activation in the Lkb1-deleted stroma contributes to the phenotype. Loss of PTEN, an upstream regulator of mTORC1 signaling, along with Lkb1 deletion significantly increased tumor burden in uteri and induced tumorigenesis in the cervix and vagina. These studies show that LKB1/TSC1/TSC2/mTORC1 signaling in mesenchymal cells is important for the maintenance of epithelial integrity and suppression of carcinogenesis in adjacent epithelial cells. Because similar changes in the stromal population are also observed in human oviductal/ovarian adenoma and endometrial adenocarcinoma patients, we predict that dysregulated mTORC1 activity by upstream mechanisms similar to those described in these model systems contributes to the pathogenesis of these human diseases.

          Author Summary

          Peutz-Jeghers Syndrome patients have autosomal dominant mutations in the LKB1/STK11 gene and are prone to developing cancer, predominantly in the intestinal tract but also in other tissues, including the reproductive tracts and gonads. To elucidate the mechanisms disrupted by the loss of LKB1 in the reproductive tract, we have developed a mouse model with deletion of Lkb1 specifically in stromal cells of gynecologic tissues. These mice show stromal cell expansion and develop oviductal adenomas and endometrial cancer. Deletion of either Tsc1 or Tsc2 genes, which are mutated in patients with Tuberous Sclerosis Complex and whose protein products are indirect downstream targets of LKB1 signaling, resulted in some of the same defects observed in Lkb1 mutant mice. Activation of mammalian Target Of Rapamycin Complex 1 (mTORC1), a common effector of disrupted LKB1, TSC1, and TSC2 signaling, was observed in all mutant tissues examined, suggesting that uninhibited mTORC1 activity is necessary for the phenotypes. Suppression of mTORC1 signaling by rapamycin reduced tumor burden in Lkb1 mutant mice, confirming the link between dysregulation of mTORC1 to development of the Lkb1 mutant phenotype and suggesting that therapeutic targeting of LKB1/TSC1/TSC2/mTORC1 signaling would benefit human Peutz-Jeghers Syndrome and Tuberous Sclerosis patients with reproductive tract disease.

          Related collections

          Most cited references56

          • Record: found
          • Abstract: found
          • Article: not found

          The LKB1 tumor suppressor negatively regulates mTOR signaling.

          Germline mutations in LKB1, TSC2, or PTEN tumor suppressor genes result in hamartomatous syndromes with shared tumor biological features. The recent observations of LKB1-mediated activation of AMP-activated protein kinase (AMPK) and AMPK inhibition of mTOR through TSC2 prompted us to examine the biochemical and biological relationship between LKB1 and mTOR regulation. Here, we report that LKB1 is required for repression of mTOR under low ATP conditions in cultured cells in an AMPK- and TSC2-dependent manner, and that Lkb1 null MEFs and the hamartomatous gastrointestinal polyps from Lkb1 mutant mice show elevated signaling downstream of mTOR. These findings position aberrant mTOR activation at the nexus of these germline neoplastic conditions and suggest the use of mTOR inhibitors in the treatment of Peutz-Jeghers syndrome.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Reconstruction of functionally normal and malignant human breast tissues in mice.

            The study of normal breast epithelial morphogenesis and carcinogenesis in vivo has largely used rodent models. Efforts at studying mammary morphogenesis and cancer with xenotransplanted human epithelial cells have failed to recapitulate the full extent of development seen in the human breast. We have developed an orthotopic xenograft model in which both the stromal and epithelial components of the reconstructed mammary gland are of human origin. Genetic modification of human stromal cells before the implantation of ostensibly normal human mammary epithelial cells resulted in the outgrowth of benign and malignant lesions. This experimental model allows for studies of human epithelial morphogenesis and differentiation in vivo and underscores the critical role of heterotypic interactions in human breast development and carcinogenesis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The AMP-activated protein kinase cascade--a unifying system for energy control.

              AMP-activated protein kinase (AMPK) is the downstream component of a protein kinase cascade that acts as an intracellular energy sensor maintaining the energy balance within the cell. This pivotal role of AMPK places it in an ideal position for regulating whole-body energy metabolism, and AMPK might play a part in protecting the body from metabolic diseases such as type 2 diabetes and obesity. Mutations in AMPK cause cardiac hypertrophy and arrhythmia. Recent findings have identified LKB1--a protein kinase that is mutated in a hereditary form of cancer--as a candidate for the upstream kinase in the AMPK cascade. AMPK could provide a link in human diseases of which the underlying cause is due to defects in energy metabolism.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS Genet
                PLoS Genet
                plos
                plosgen
                PLoS Genetics
                Public Library of Science (San Francisco, USA )
                1553-7390
                1553-7404
                August 2012
                August 2012
                16 August 2012
                : 8
                : 8
                : e1002906
                Affiliations
                [1 ]Vincent Center for Reproductive Biology, Department of Obstetrics, Gynecology, and Reproductive Biology, Massachusetts General Hospital, Boston, Massachusetts, United States of America
                [2 ]School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia
                [3 ]Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
                SA Pathology, Australia
                Author notes

                The authors have declared that no competing interests exist.

                Conceived and designed the experiments: PST JMT. Performed the experiments: PST TK-T LZ YT. Analyzed the data: PST TK-T CPC JMT. Contributed reagents/materials/analysis tools: CPC. Wrote the paper: PST JMT.

                Article
                PGENETICS-D-12-00715
                10.1371/journal.pgen.1002906
                3420942
                22916036
                f16af8e7-2801-4563-a3ec-9012a313ba6e
                Copyright @ 2012

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 21 March 2012
                : 3 July 2012
                Page count
                Pages: 14
                Funding
                This work was supported by funding from NICHD (HD052701) and by Vincent Memorial Research Funds to JMT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article
                Biology
                Genetics
                Human Genetics
                Autosomal Dominant
                Cancer Genetics
                Gene Networks
                Genetic Mutation
                Model Organisms
                Animal Models
                Mouse
                Medicine
                Obstetrics and Gynecology
                Gynecologic Cancers
                Oncology
                Cancer Risk Factors
                Genetic Causes of Cancer
                Cancers and Neoplasms
                Gynecological Tumors

                Genetics
                Genetics

                Comments

                Comment on this article